Close Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

Commodore Capital

Investor type Venture Capital


Unlock datapoints

Portfolio analytics



News & Media

Add fund to favorites
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.

Looking for a perfect list of funds?

Get recommendations from our smart algorithm

Get the list
Total investments 14
Average round size
The average size of a deal this fund participated in
Portfolio companies 12
Rounds per year 3.50
Lead investments 0
Follow on index
How often the fund supports its portfolio startups at next rounds
Exits 9
Key employees Soon
Stages of investment
Early Stage Venture

Areas of investment

  • Biotechnology
  • Therapeutics
  • Health Care
  • Life Science
  • Medical

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Commodore Capital:
Typical Co-investors
Commodore Capital is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Commodore Capital:
There are no funds here. If we find new data, we will add it here.

Funds with similar focus

Funds from United States
Funds with similar focus located in United States:
Funds with the same geo focus
Funds with similar geography of portfolio companies:
Funds doing lead investments
Funds with similar focus acting as lead investors:

Look at other 50 related and similar funds Collapse list
Fund NameLocation
1818 Venture Capital Guernsey, Guernsey, NA - Guernsey
Acorn Bioventures New York, New York, United States
Acuity Brands Atlanta, Georgia, United States
Bincot -
Cheval Holdings -
Concord Partners Massachusetts, United States, Wellesley
GeneScience Pharmaceuticals -
Hacking Health Accelerator Canada, Montréal, Quebec
Hermann Companies Arkansas, Paragould, United States
Kissei Pharmaceutical Japan, Matsumoto, Nagano Prefecture
MEST Express accelerator Accra, Ghana, Greater Accra
Old Ironsides Energy Boston, Massachusetts, United States
Ontario Pension Board Canada, Ontario, Toronto
Orgain California, Irvine, United States
Technologies SAS -
Tokyo Commodity Exchange -
Trends Media -
Yiguo Group Changning, China, Shanghai

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation


$153M22 Feb 2023 Paris, Ile-de-France, France


Life Science
$60M10 Oct 2022 San Diego, California, United States


$75M04 Oct 2022 New York, New York, United States


Health Care
$150M19 Sep 2022 California, United States


Health Care
Health Diagnostics
$100M16 May 2022 Minnesota, United States

Third Harmonic Bio

Life Science
$105M16 Jan 2022 Cambridge, Massachusetts, United States

Nimbus Therapeutics

Alternative Medicine
Health Care
$105M13 Jul 2021 Cambridge, Massachusetts, United States

Satsuma Pharmaceuticals

$80M01 Mar 2021 South San Francisco, California, United States

Shoreline Biosciences

Life Science
$43M07 Feb 2021 San Diego, California, United States
Nimbus Therapeutics Announces $105 Million Private Financing to Advance Pipeline Including Multiple Clinical Programs

– Nimbus Therapeutics, a biotechnology company designing breakthrough medicines through structure-based drug discovery and development, announced the closing of a $105 million private financing round.
– The round was led by BVF Partners L.P., with participation from existing investors including RA Capital Management and Atlas Venture.
Access Biotechnology, Commodore Capital, Logos Capital, Surveyor Capital (a Citadel company), and a large alternative asset manager joined as new investors in this financing.
– In addition to the Phase 2 studies of Nimbus’ allosteric TYK2 inhibitor, the financing will support a first-in-human study of the company’s HPK1 inhibitor candidate in cancer patients with solid tumors, which will begin later this year, and will accelerate preclinical programs against multiple targets in oncology and immunology.


  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Commodore Capital?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: